Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression
| Autor: | Staffan Nilsson, Elias Eriksson, Fredrik Hieronymus, J. F. Emilsson |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male medicine.medical_specialty Citalopram Placebo behavioral disciplines and activities 03 medical and health sciences Cellular and Molecular Neuroscience 0302 clinical medicine Internal medicine mental disorders medicine Humans Serotonin and Noradrenaline Reuptake Inhibitors Psychiatry Molecular Biology Depression (differential diagnoses) Randomized Controlled Trials as Topic Depressive Disorder Major Sertraline Fluoxetine Venlafaxine Hydrochloride Reproducibility of Results Middle Aged Cyclohexanols Paroxetine 030227 psychiatry Affect Psychiatry and Mental health Antidepressant Female Original Article Psychopharmacology Psychology Selective Serotonin Reuptake Inhibitors 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Molecular Psychiatry |
| ISSN: | 1476-5578 1359-4184 |
| Popis: | The recent questioning of the antidepressant effect of selective serotonin reuptake inhibitors (SSRIs) is partly based on the observation that approximately half of company-sponsored trials have failed to reveal a significant difference between active drug and placebo. Most of these have applied the Hamilton depression rating scale to assess symptom severity, the sum score for its 17 items (HDRS-17-sum) serving as effect parameter. In this study, we examined whether the negative outcomes of many SSRI trials may be partly caused by the use of this frequently questioned measure of response. We undertook patient-level post-hoc analyses of 18 industry-sponsored placebo-controlled trials regarding paroxetine, citalopram, sertraline or fluoxetine, and including in total 6669 adults with major depression, the aim being to assess what the outcome would have been if the single item depressed mood (rated 0–4) had been used as a measure of efficacy. In total, 32 drug-placebo comparisons were reassessed. While 18 out of 32 comparisons (56%) failed to separate active drug from placebo at week 6 with respect to reduction in HDRS-17-sum, only 3 out of 32 comparisons (9%) were negative when depressed mood was used as an effect parameter (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink